ijms-logo

Journal Browser

Journal Browser

Special Issue "Cancer Immunotherapy: Recent Advances and Prospects"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 28 February 2022.

Special Issue Editors

Prof. Dr. Il-Kang Na
E-Mail Website
Guest Editor
Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin
German Cancer Consortium (DKTK), partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany
Experimental and Clinical Research Center (ECRC), Berlin, Germany
Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany
Interests: cancer immuotherapy; biomarker; immune modulation and reconstitution
PD Dr. Antonia Busse
E-Mail Website
Guest Editor
Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin
German Cancer Consortium (DKTK), partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany
Interests: cancer immuotherapy; biomarker; immune modulation and reconstitution
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

In the era of emerging cancer immunotherapy, new challenges have arisen due to treatment-induced resistance mechanisms on the tumor side and alterations of innate and adaptive patients’ immune systems. Each cancer-specific therapy as well as each immunotherapy results in dynamic tumor immune interaction. With a better understanding of these interactions, not only novel combination therapies but also smart sequencing strategies can be developed.

This Special Issue aims to publish research articles, reviews, and perspectives that concentrate on clinical/translational cancer immunotherapy, including in vitro and in vivo studies about novel immunotherapeutic approaches, therapy-induced immunomodulation and immunotherapy biomarkers.

Prof. Dr. Il-Kang Na
PD Dr. Antonia Busse
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Immunotherapy
  • Checkpoint inhibitor therapy
  • Adoptive T cell therapy
  • Resistance mechanisms
  • Immune modulation
  • Immune reconstitution
  • Combination therapy
  • Immunosuppression
  • Biomarker
  • In vitro studies
  • In vivo studies

Published Papers

This special issue is now open for submission.
Back to TopTop